FK 506 for liver, kidney, and pancreas transplantation.

PubWeight™: 13.70‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMC 2966318)

Published in Lancet on October 28, 1989

Authors

T E Starzl1, S Todo, J Fung, A J Demetris, R Venkataramman, A Jain

Author Affiliations

1: Department of Surgery, University Health Center of Pittsburgh, Pennsylvania.

Articles citing this

(truncated to the top 100)

Kidney transplantation under FK 506. JAMA (1990) 7.45

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A (1990) 3.70

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1991) 2.97

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ (1999) 2.65

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

Allo-limbal transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol (1999) 2.57

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31

Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20

Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Liver transplantation in 100 children: Cambridge and King's College Hospital series. BMJ (1992) 1.90

Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg (2001) 1.89

The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg (2002) 1.81

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71

Transplantation. JAMA (1990) 1.71

Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. Transplant Proc (1990) 1.71

Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61

The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60

Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59

Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57

Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56

FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery (1991) 1.49

Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology (1991) 1.48

Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. EMBO J (1995) 1.47

Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45

Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44

A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40

FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol (1992) 1.32

The history of cytomegalovirus and its diseases. Med Microbiol Immunol (2007) 1.32

The effect of FK 506 and CyA on the Lewis rat renal ischemia model. Transplant Proc (1990) 1.28

Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23

Long-term survival of donor-specific pancreatic islet xenografts in fully xenogeneic chimeras (WF rat----B10 mouse). Transplantation (1992) 1.23

Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. Mol Cell Biol (1991) 1.22

Hepatic Retransplantation--an analysis of risk factors associated with outcome. Transplantation (1996) 1.22

Cyclosporin: use outside transplantation. BMJ (1991) 1.22

Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet (1993) 1.21

Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg (1992) 1.18

Tacrolimus in pediatric renal transplantation. Transplantation (1996) 1.18

The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc (1991) 1.16

Disease gravity and urgency of need as guidelines for liver allocation. Hepatology (1994) 1.16

Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc (1990) 1.14

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc (1995) 1.13

Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. Transplantation (1991) 1.13

Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology (1992) 1.12

One thousand liver transplants. The lessons learned. Ann Surg (1994) 1.12

Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. Proc Natl Acad Sci U S A (1991) 1.10

An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. J Clin Pharmacol (1993) 1.09

The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc (1991) 1.08

Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. Transplant Proc (1990) 1.08

Chimerism and tolerance in transplantation. Proc Natl Acad Sci U S A (2004) 1.07

Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506? Cell Commun Signal (2009) 1.06

Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol (2010) 1.04

The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. Immunology (1990) 1.03

FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol (1993) 1.02

Liver transplantation in the UK. World J Gastroenterol (2001) 1.02

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02

Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. Transplant Proc (1991) 1.01

FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. Transplant Proc (1991) 1.00

FK 506 dosage in human organ transplantation. Transplant Proc (1990) 0.99

Islet xenografts in fully xenogeneic (rat----mouse) chimeras: evidence for normal regulation of function in a xenogeneic mouse environment. Surgery (1992) 0.98

Themes of liver transplantation. Hepatology (2010) 0.98

Liver transplantation: fifty years of experience. World J Gastroenterol (2014) 0.98

Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res (2007) 0.97

Preliminary experience with FK506 in thoracic transplantation. Transplantation (1991) 0.97

Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation (2000) 0.95

Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol (2001) 0.95

Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg (1996) 0.95

One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc (1995) 0.94

Orthotopic liver transplantation for congenital biliary atresia. An 11-year, single-center experience. Ann Surg (1996) 0.93

The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology (2006) 0.93

FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc (1991) 0.93

Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. Transplant Proc (1990) 0.93

Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation (2000) 0.92

Pediatric liver transplantation. World J Gastroenterol (2009) 0.92

The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. Transplantation (1992) 0.91

History of clinical transplantation. World J Surg (2000) 0.91

Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc (1993) 0.90

Tacrolimus (FK506)-Associated Renal Pathology. Adv Anat Pathol (1997) 0.90

Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles. World J Surg (2000) 0.90

Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol (1990) 0.89

Articles by these authors

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Kidney transplantation under FK 506. JAMA (1990) 7.45

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Liver transplantation (1). N Engl J Med (1989) 4.53

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Liver transplantation before 1 year of age. J Pediatr (1987) 3.15

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Liver transplantation (2). N Engl J Med (1989) 2.93

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87

Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82

Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48

Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40

Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31